|
|
Blood, 1 July 2008, Vol. 112, No. 1, pp. 11-18.
 Previous Article | Table of Contents | Next Article 
ASH 50TH ANNIVERSARY REVIEW
Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura
J. Evan Sadler1
1 Department of Medicine, Department of Biochemistry and Molecular Biophysics, and Howard Hughes Medical Institute, Washington University School of Medicine, St Louis, MO
Discoveries during the past decade have revolutionized our understanding of idiopathic thrombotic thrombocytopenic purpura (TTP). Most cases in adults are caused by acquired autoantibodies that inhibit ADAMTS13, a metalloprotease that cleaves von Willebrand factor within nascent platelet-rich thrombi to prevent hemolysis, thrombocytopenia, and tissue infarction. Although approximately 80% of patients respond to plasma exchange, which removes autoantibody and replenishes ADAMTS13, one third to one half of survivors develop refractory or relapsing disease. Intensive immunosuppressive therapy with rituximab appears to be effective as salvage therapy, and ongoing clinical trials should determine whether adjuvant rituximab with plasma exchange also is beneficial at first diagnosis. A major unanswered question is whether plasma exchange is effective for the subset of patients with idiopathic TTP who do not have severe ADAMTS13 deficiency.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
P. J. Hoskin, L. Lowry, A. Horwich, A. Jack, B. Mead, B. W. Hancock, P. Smith, W. Qian, P. Patrick, B. Popova, et al.
Randomized Comparison of the Stanford V Regimen and ABVD in the Treatment of Advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244
J. Clin. Oncol.,
November 10, 2009;
27(32):
5390 - 5396.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B.-Q. Zhao, A. K. Chauhan, M. Canault, I. S. Patten, J. J. Yang, M. Dockal, F. Scheiflinger, and D. D. Wagner
von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke
Blood,
October 8, 2009;
114(15):
3329 - 3334.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Edwards-Bennett, L. M. Jacks, C. H. Moskowitz, E. J. Wu, Z. Zhang, A. Noy, C. S. Portlock, D. J. Straus, A. D. Zelenetz, and J. Yahalom
Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience
Ann. Onc.,
September 16, 2009;
(2009)
mdp337v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Moncada-Pazos, A. J. Obaya, M. F. Fraga, C. G. Viloria, G. Capella, M. Gausachs, M. Esteller, C. Lopez-Otin, and S. Cal
The ADAMTS12 metalloprotease gene is epigenetically silenced in tumor cells and transcriptionally activated in the stroma during progression of colon cancer
J. Cell Sci.,
August 15, 2009;
122(16):
2906 - 2913.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Burrus, E. F.M. Wijdicks, and A. A. Rabinstein
Brain lesions are most often reversible in acute thrombotic thrombocytopenic purpura
Neurology,
July 7, 2009;
73(1):
66 - 70.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Li, W. Zhang, H. Ren, X. Pan, and N. Chen
Malignant hypertension complicated by acute renal failure
BMJ Case Reports,
June 14, 2009;
2009(jun11_2):
bcr1020081116 - bcr1020081116.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
T. D. Nightingale, K. Pattni, A. N. Hume, M. C. Seabra, and D. F. Cutler
Rab27a and MyRIP regulate the amount and multimeric state of VWF released from endothelial cells
Blood,
May 14, 2009;
113(20):
5010 - 5018.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Palla, S. Lavoretano, R. Lombardi, I. Garagiola, M. Karimi, A. Afrasiabi, M. Ramzi, R. De Cristofaro, and F. Peyvandi
The first deletion mutation in the TSP1-6 repeat domain of ADAMTS13 in a family with inherited thrombotic thrombocytopenic purpura
Haematologica,
February 1, 2009;
94(2):
289 - 293.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
